SS Innovations International, Inc. (NASDAQ: SSII)

SS Innovations International, Inc. (NASDAQ: SSII) develops differentiated surgical robotic technologies, highlighted by its advanced, cost-efficient SSi Mantra surgical robotic system. Spearheaded by a team of visionary engineers and Dr. Sudhir Srivastava, an acclaimed robotic cardiac surgeon and the company’s founder, Chairman and Chief Executive Officer, the SSi Mantra features differentiated capabilities in areas such as telesurgery, cardiac surgery and pediatric procedures. The SSi Mantra’s broad-based surgical robotic applications, modularity, user friendliness, training capabilities, clinical track record and relative cost advantages have contributed to its early commercial success.

SS Innovations is a rapidly growing American company headquartered in India and expanding globally with an eye on democratizing access to cutting-edge surgical robotic technologies. After commencing commercial operations in late 2022, the company’s annual revenue has grown from approximately $5.9 million in 2023 to $42.5 million in 2025, corresponding to a compounded annual growth rate of 169%. Nearly 500 employees and more than 90,000 square feet of world-class R&D and manufacturing facilities support the company’s growth.

The SSi Mantra has been approved for commercial use in 14 countries, and the company currently is pursuing regulatory approval of the SSi Mantra from the U.S. Food and Drug Administration as well as a European Union CE marking.

SSi Mantra

The SSi Mantra is SS Innovations’ proprietary surgical robotic system and serves as the foundation of the company’s technology portfolio. As of May 31, 2026, the SSi Mantra global installed base totaled 210 systems. The platform features a modular architecture with three to five robotic arms, an open-faced surgeon command center, a 3D 4K visualization system and integrated imaging capabilities designed to support a wide range of minimally invasive procedures.

The system has been validated for use across numerous surgical specialties, including general surgery, urology, gynecology, colorectal, cardiac, gastrointestinal, head and neck, thoracic and breast and plastic surgery procedures. According to company disclosures, the SSi Mantra has been utilized in more than 11,700 surgeries, including hundreds of cardiac procedures, pediatric procedures and telesurgeries, and has been clinically validated across more than 170 different surgical procedure types.

SS Innovations also developed the SSi MantrAsana tele-surgeon console — a portable, compact chair-based version of the surgeon command center designed to facilitate remote surgery. The company’s SSi Mantra platform has been utilized in more than 175 telesurgeries, including complex cardiac telesurgeries and multiple long-distance international procedures. In May 2026, a robot-assisted heart procedure was successfully performed with the SSi Mantra across approximately 12,500 miles (20,000 kilometers) of fiber network distance between Guyana and India, making it the world’s longest-distance robotic telesurgery ever conducted. The SSi Mantra’s tele-surgical architecture has been specifically designed to maintain procedural precision across high-latency, long-haul network environments.

SSi Mudra

SSi Mudra is the company’s portfolio of robotic surgical instruments designed for use with the SSi Mantra platform. The product line includes more than 40 instrument types spanning monopolar and bipolar cautery instruments, clip appliers, needle drivers, graspers and specialty instruments developed for robotic cardiothoracic procedures.

The instrument portfolio supports a broad range of surgical applications and includes tools developed specifically for pediatric and cardiac surgery. SS Innovations positions SSi Mudra as an integral component of its surgical robotics ecosystem, providing procedure-specific instrumentation across multiple specialties.

SS Innovations receives recurring revenue from the sale of robotic surgical instruments. Recurring revenue represented approximately 15% of total revenue in 2025 per company disclosures.

SSi Maya

SSi Maya is a mixed-reality surgical platform developed to support visualization, training and procedural planning. The platform incorporates technologies such as 3D holographic imaging, virtual surgery tools, tele-proctoring capabilities and artificial intelligence-based anatomy segmentation.

SS Innovations designed SSi Maya to support surgeon education and procedural preparation while expanding access to advanced training resources. The platform is intended to complement the company’s robotic surgery technologies by providing immersive digital tools for surgical learning and collaboration.

A subsidiary of SS Innovations, the SS International Center for Robotics Surgery (SSICRS), graduated its first class in June 2026 from a specialized cardiac training program designed to provide surgeons, medical residents, anesthesiologists, and other healthcare professionals with theoretical classroom instruction and practical hands-on learning in robotic-assisted surgery. The center’s virtual and in-person instruction leverages both the SSi Mantra and SSi Maya. The company aims for SSICRS to become one of the world’s premier training institutes for robotic surgery.

Market Opportunity

According to Markets and Markets, the global surgical robotics market was valued at approximately $12.0 billion in 2024 and is projected to grow to approximately $27.1 billion by 2030, representing a compound annual growth rate of 14.7%.

According to estimates cited in the company’s investor presentation, less than 1% of surgeries performed globally are currently robotic procedures. The company believes this low level of penetration highlights a substantial opportunity for broader adoption of robotic-assisted surgery as healthcare providers seek minimally invasive treatment options and advanced surgical technologies.

The company further notes that, while approximately 95% of the world’s population resides outside the United States, Europe and Japan, only about 5% of installed surgical robotic systems are located in those regions. SS Innovations has positioned its technology portfolio to target healthcare markets that have historically experienced limited access to robotic surgery platforms.

Leadership Team

Dr. Sudhir Srivastava, Founder, Chairman and CEO, is a robotic cardiac surgeon and entrepreneur who founded SS Innovations to advance the accessibility of robotic surgery technologies. He has performed one of the largest volumes of robotic cardiac procedures globally and pioneered several robotic beating-heart TECAB procedures, including multiple world-first operations. In addition to leading SS Innovations, he has trained surgical teams around the world and has been actively involved in the development and advancement of robotic-assisted surgical techniques for decades. As of June 12, 2026, Dr. Srivastava owned approximately 108.6 million SSII shares, or 54.3% of total shares outstanding.

Dr. Frederic Moll, Vice Chairman, is a physician, entrepreneur and medical robotics pioneer widely recognized for his contributions to minimally invasive surgery. He co-founded Intuitive Surgical and helped develop the da Vinci robotic-assisted surgery system. Dr. Moll also founded Hansen Medical and Auris Health and has served on the boards of multiple healthcare technology companies focused on robotics, imaging and cancer treatment technologies. As of June 12, 2026, Dr. Moll owned approximately 20.8 million SSII shares, or 10.4% of total shares outstanding.

Dr. Vishwajyoti Srivastava, Chief Executive Officer – APAC and Board Member, has been involved in robotic surgery technologies since 2008. His work has included the development of robotic surgery training platforms, tele-mentoring initiatives and advanced medical visualization systems. He previously led development of the OMNI 3D Medical Visualization platform and currently oversees activities supporting the continued advancement and expansion of SS Innovations’ technology platform.

Barry Cohen, Chief Operating Officer – Americas and Board Member, brings decades of experience in public-company management, medical technology and capital markets. He founded Avra Medical Robotics and has held leadership positions with several public and private companies throughout his career. His background includes more than 50 years managing industrial and technology-focused businesses and extensive experience in securities and corporate operations.